Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Plos One|August 29, 2024
Long-term brain fog and cognitive impairment in previously hospitalized COVID-19 patientsBarbara Junco, Daniel Samano Martin Del Campo, Vela Karakeshishyan, et al.Lung Cancer (Amsterdam, Netherlands)|June 15, 2026
Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA studyTerufumi Kato, Xiaorong Dong, Toshiaki Takahashi, et al.European Journal of Cancer (Oxford, England : 1990)|April 22, 2026
Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapyEdurne Arriola, Ignacio Casarini, Mustafa Özgüroğlu, et al.JTO Clinical and Research Reports|February 19, 2024
Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup AnalysisJie Wang, Yi-Long Wu, Shun Lu, et al.Neurocritical Care|October 23, 2024
A Survey of Surrogates and Health Care Professionals Indicates Support of Cognitive Motor Dissociation-Assisted PrognosticationGregory A Heinonen, Jerina C Carmona, Lauren Grobois, et al.The New England Journal of Medicine|June 5, 2023
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLCMasahiro Tsuboi, Roy S Herbst, Thomas John, et al.Targeted Oncology|March 11, 2024
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLCMasahiro Tsuboi, Roy S Herbst, Thomas John, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2023
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA TrialRoy S Herbst, Yi-Long Wu, Thomas John, et al.Pageof 1